Quest Diagnostics Inc
DGX- Exchange
- NYSE
- Industry
- Services-Medical Laboratories
- SEC CIK
- 0001022079
In the last 90 days, Quest Diagnostics Inc insiders filed 0 open-market purchases and 3 sales; 1,112 institutions reported holding it in 13F filings for Q2 2026, worth $22.2B in total; no superinvestor holds it.
Holders of 5% or more of DGX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Quest Diagnostics Inc, largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 8.40%9.31M shares | – | Apr 17, 20251 filing | Apr 17, 2025 | SEC |
| Price T Rowe Associates Inc | 13G/A | 6.50%7.21M shares | +1.10 ppfrom 5.40% | May 14, 20252 filings | Aug 14, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
3 Schedule 13D and 13G filings on Quest Diagnostics Inc, newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 20251:07 PM ET | Price T Rowe Associates Inc | 13G/A | 6.50%7.21M shares | +1.10 ppfrom 5.40% | Jun 30, 2025 | SEC |
| May 14, 202510:45 AM ET | Price T Rowe Associates Inc | 13G | 5.40%6.00M shares | New | Mar 31, 2025 | SEC |
| Apr 17, 20259:35 AM ET | BlackRock, Inc. | 13G/A | 8.40%9.31M shares | – | Mar 31, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Quest Diagnostics Inc shares.
No Form 144 notices for Quest Diagnostics Inc are on file.